Advertisement
Screener

INNOVIVA, INC. (INVA) Share-based Payment Arrangement, Expense

2.8 / 5 stars · 68/120 Roast Me

INNOVIVA, INC. Share-based Payment Arrangement, Expense

INNOVIVA, INC. (INVA) reported Share-based Payment Arrangement, Expense of $4.74 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-05

  • INNOVIVA, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $4.74M, a 95.83% increase year-over-year.
  • INNOVIVA, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $2.57M, a 19.56% increase year-over-year.
  • INNOVIVA, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $2.50M, a 49.61% increase year-over-year.
  • INNOVIVA, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $2.38M, a 48.47% increase year-over-year.
  • INNOVIVA, INC. share-based payment arrangement, expense for fiscal 2025 was $9.45M, a 48.29% increase from fiscal 2024.
  • INNOVIVA, INC. share-based payment arrangement, expense for fiscal 2024 was $6.37M, a 9.20% increase from fiscal 2023.
  • INNOVIVA, INC. share-based payment arrangement, expense for fiscal 2023 was $5.84M, a 20.55% decline from fiscal 2022.
  • INNOVIVA, INC. share-based payment arrangement, expense for fiscal 2022 was $7.35M, a 264.25% increase from fiscal 2021.
Period endShare-based Payment Arrangement, Expense 3 monthShare-based Payment Arrangement, Expense 6 monthShare-based Payment Arrangement, Expense 6 month as first filedShare-based Payment Arrangement, Expense 9 monthShare-based Payment Arrangement, Expense 12 month
2026-06-30$4.74M
10-Q · filed 2026-08-05
$7.31M
10-Q · filed 2026-08-05
$9.81M
derived: sum of 3 quarters · filed 2026-08-05
$12.19M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$2.57M
10-Q · filed 2026-05-06
$5.07M
derived: sum of 2 quarters · filed 2026-05-06
$7.45M
derived: sum of 3 quarters · filed 2026-05-06
$9.87M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$2.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$4.88M
derived: sum of 2 quarters · filed 2026-02-25
$7.30M
derived: sum of 3 quarters · filed 2026-08-05
$9.45M
10-K · filed 2026-02-25
2025-09-30$2.38M
10-Q · filed 2025-11-05
$4.80M
derived: sum of 2 quarters · filed 2026-08-05
$6.95M
10-Q · filed 2025-11-05
$8.62M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$2.42M
10-Q · filed 2026-08-05
$4.57M
10-Q · filed 2026-08-05
$6.24M
derived: sum of 3 quarters · filed 2026-08-05
$7.84M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$2.15M
10-Q · filed 2026-05-06
$3.82M
derived: sum of 2 quarters · filed 2026-05-06
$5.42M
derived: sum of 3 quarters · filed 2026-05-06
$7.07M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31$1.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$3.28M
derived: sum of 2 quarters · filed 2026-02-25
$4.92M
derived: sum of 3 quarters · filed 2026-02-25
$6.37M
10-K · filed 2026-02-25
2024-09-30$1.60M
10-Q · filed 2025-11-05
$3.25M
derived: sum of 2 quarters · filed 2025-11-05
$4.70M
10-Q · filed 2025-11-05
$5.98M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30$1.64M
10-Q · filed 2025-08-06
$3.10M
10-Q · filed 2025-08-06
$4.38M
derived: sum of 3 quarters · filed 2026-02-25
$5.82M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31$1.46M
10-Q · filed 2025-05-07
$2.73M
derived: sum of 2 quarters · filed 2026-02-25
$4.17M
derived: sum of 3 quarters · filed 2026-02-25
$5.69M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31$1.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$2.72M
derived: sum of 2 quarters · filed 2026-02-25
$4.24M
derived: sum of 3 quarters · filed 2026-02-25
$5.84M
10-K · filed 2026-02-25
2023-09-30$1.44M
10-Q · filed 2024-11-06
$2.96M
derived: sum of 2 quarters · filed 2024-11-06
$4.56M
10-Q · filed 2024-11-06
$5.89M
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30$1.52M
10-Q · filed 2024-07-31
$3.12M
10-Q · filed 2024-07-31
$4.44M
derived: sum of 3 quarters · filed 2025-02-26
$8.16M
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31$1.60M
10-Q · filed 2024-05-08
$2.92M
derived: sum of 2 quarters · filed 2025-02-26
$6.64M
derived: sum of 3 quarters · filed 2025-02-26
$7.99M
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31$1.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
$5.04M
derived: sum of 2 quarters · filed 2025-02-26
$6.39M
derived: sum of 3 quarters · filed 2025-02-26
$7.35M
10-K · filed 2025-02-26
2022-09-30$3.72M
10-Q · filed 2023-11-01
$5.07M
derived: sum of 2 quarters · filed 2023-11-01
$6.02M
10-Q · filed 2023-11-01
$6.58M
derived: sum of 4 quarters · filed 2024-03-05
2022-06-30$1.35M
10-Q · filed 2023-08-02
$2.30M
10-Q · filed 2023-08-02
$2.86M
derived: sum of 3 quarters · filed 2024-03-05
$3.40M
derived: sum of 4 quarters · filed 2024-03-05
2022-03-31$954.00K
10-Q · filed 2023-05-09
$1.51M
derived: sum of 2 quarters · filed 2024-03-05
$2.05M
derived: sum of 3 quarters · filed 2024-03-05
$2.52M
derived: sum of 4 quarters · filed 2024-03-05
2021-12-31$554.00K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05
$1.10M
derived: sum of 2 quarters · filed 2024-03-05
$1.57M
derived: sum of 3 quarters · filed 2024-03-05
$2.02M
10-K/A · filed 2024-03-05
2021-09-30$542.00K
10-Q · filed 2022-11-09
$1.01M
derived: sum of 2 quarters · filed 2022-11-09
$1.46M
10-Q · filed 2022-11-09
2021-06-30$470.00K
10-Q · filed 2022-07-27
$921.00K
10-Q · filed 2022-07-27
2021-03-31$451.00K
10-Q · filed 2022-05-05
2020-12-31$1.70M
10-K · filed 2023-02-28
2019-12-31$2.06M
10-K/A · filed 2022-03-17
2018-12-31$486.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
-$388.00K
derived: sum of 2 quarters · filed 2021-02-25
$1.06M
derived: sum of 3 quarters · filed 2021-02-25
$3.23M
10-K · filed 2021-02-25
2018-09-30-$874.00K
10-Q · filed 2018-10-31
$578.00K
derived: sum of 2 quarters · filed 2018-10-31
$2.75M
10-Q · filed 2018-10-31
$5.17M
derived: sum of 4 quarters · filed 2020-02-19
2018-06-30$1.45M
10-Q · filed 2018-07-26
$3.62M
10-Q · filed 2018-07-26
$6.05M
derived: sum of 3 quarters · filed 2020-02-19
$8.52M
derived: sum of 4 quarters · filed 2020-02-19
2018-03-31$2.17M
10-Q · filed 2018-05-04
$4.60M
derived: sum of 2 quarters · filed 2020-02-19
$7.07M
derived: sum of 3 quarters · filed 2020-02-19
$9.49M
derived: sum of 4 quarters · filed 2020-02-19
2017-12-31$2.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19
$4.90M
derived: sum of 2 quarters · filed 2020-02-19
$7.33M
derived: sum of 3 quarters · filed 2020-02-19
$9.83M
10-K · filed 2020-02-19
2017-09-30$2.47M
10-Q · filed 2018-10-31
$4.90M
derived: sum of 2 quarters · filed 2018-10-31
$7.41M
10-Q · filed 2018-10-31
$9.28M
derived: sum of 4 quarters · filed 2019-02-19
2017-06-30$2.43M
10-Q · filed 2018-07-26
$4.93M
10-Q · filed 2018-07-26
$6.81M
derived: sum of 3 quarters · filed 2019-02-19
$8.53M
derived: sum of 4 quarters · filed 2019-02-19
2017-03-31$2.51M
10-Q · filed 2018-05-04
$4.38M
derived: sum of 2 quarters · filed 2019-02-19
$6.10M
derived: sum of 3 quarters · filed 2019-02-19
$8.94M
derived: sum of 4 quarters · filed 2019-02-19
2016-12-31$1.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19
$3.59M
derived: sum of 2 quarters · filed 2019-02-19
$6.43M
derived: sum of 3 quarters · filed 2019-02-19
$8.30M
10-K · filed 2019-02-19
2016-09-30$1.72M
10-Q · filed 2017-11-03
$4.56M
derived: sum of 2 quarters · filed 2017-11-03
$6.42M
10-Q · filed 2017-11-03
$8.07M
derived: sum of 4 quarters · filed 2018-02-23
2016-06-30$2.84M
10-Q · filed 2017-08-08
$4.71M
10-Q · filed 2017-08-08
$4.70M
10-Q · filed 2016-08-04
$6.36M
derived: sum of 3 quarters · filed 2018-02-23
$7.82M
derived: sum of 4 quarters · filed 2018-02-23
2016-03-31$1.86M
10-Q · filed 2017-05-05
$3.51M
derived: sum of 2 quarters · filed 2018-02-23
$4.98M
derived: sum of 3 quarters · filed 2018-02-23
$6.80M
derived: sum of 4 quarters · filed 2018-02-23
2015-12-31$1.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23
$3.12M
derived: sum of 2 quarters · filed 2018-02-23
$4.94M
derived: sum of 3 quarters · filed 2018-02-23
$6.87M
10-K · filed 2018-02-23
2015-09-30$1.47M
10-Q · filed 2016-11-03
$3.29M
derived: sum of 2 quarters · filed 2016-11-03
$5.22M
10-Q · filed 2016-11-03
$6.60M
derived: sum of 4 quarters · filed 2017-02-28
2015-06-30$1.82M
10-Q · filed 2016-08-04
$3.75M
10-Q · filed 2016-08-04
$5.13M
derived: sum of 3 quarters · filed 2017-02-28
$9.86M
derived: sum of 4 quarters · filed 2017-02-28
2015-03-31$1.93M
10-Q · filed 2016-05-05
$3.31M
derived: sum of 2 quarters · filed 2017-02-28
$8.04M
derived: sum of 3 quarters · filed 2017-02-28
$15.79M
derived: sum of 4 quarters · filed 2017-02-28
2014-12-31$1.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28
$6.11M
derived: sum of 2 quarters · filed 2017-02-28
$13.86M
derived: sum of 3 quarters · filed 2017-02-28
$27.39M
10-K · filed 2017-02-28
2014-09-30$4.73M
10-Q · filed 2015-11-05
$12.48M
derived: sum of 2 quarters · filed 2015-11-05
$26.01M
10-Q · filed 2015-11-05
$32.00M
derived: sum of 4 quarters · filed 2016-02-24
2014-06-30$7.75M
10-Q · filed 2015-08-06
$21.28M
10-Q · filed 2015-08-06
$27.27M
derived: sum of 3 quarters · filed 2016-02-24
$33.71M
derived: sum of 4 quarters · filed 2016-02-24
2014-03-31$13.54M
10-Q · filed 2015-05-08
$19.52M
derived: sum of 2 quarters · filed 2016-02-24
$25.96M
derived: sum of 3 quarters · filed 2016-02-24
$33.13M
derived: sum of 4 quarters · filed 2016-02-24
2013-12-31$5.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24
$12.43M
derived: sum of 2 quarters · filed 2016-02-24
$19.59M
derived: sum of 3 quarters · filed 2016-02-24
$25.69M
10-K · filed 2016-02-24
2013-09-30$6.45M
10-Q · filed 2014-11-04
$13.61M
derived: sum of 2 quarters · filed 2014-11-04
$19.70M
10-Q · filed 2014-11-04
$25.44M
derived: sum of 4 quarters · filed 2015-02-27
2013-06-30$7.16M
10-Q · filed 2014-08-07
$13.26M
10-Q · filed 2014-08-07
$19.00M
derived: sum of 3 quarters · filed 2015-02-27
$24.83M
derived: sum of 4 quarters · filed 2015-02-27
2013-03-31$6.09M
10-Q · filed 2014-05-07
$11.83M
derived: sum of 2 quarters · filed 2015-02-27
$17.66M
derived: sum of 3 quarters · filed 2015-02-27
$23.64M
derived: sum of 4 quarters · filed 2015-02-27
2012-12-31$5.74M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27
$11.57M
derived: sum of 2 quarters · filed 2015-02-27
$17.55M
derived: sum of 3 quarters · filed 2015-02-27
$23.78M
10-K · filed 2015-02-27
2012-09-30$5.83M
10-Q · filed 2013-11-01
$11.81M
derived: sum of 2 quarters · filed 2013-11-01
$18.04M
10-Q · filed 2013-11-01
$24.25M
derived: sum of 4 quarters · filed 2014-03-03
2012-06-30$5.98M
10-Q · filed 2013-08-01
$12.21M
10-Q · filed 2013-08-01
$18.42M
derived: sum of 3 quarters · filed 2014-03-03
$25.31M
derived: sum of 4 quarters · filed 2014-03-03
2012-03-31$6.24M
10-Q · filed 2013-05-01
$12.45M
derived: sum of 2 quarters · filed 2014-03-03
$19.34M
derived: sum of 3 quarters · filed 2014-03-03
$25.61M
derived: sum of 4 quarters · filed 2014-03-03
2011-12-31$6.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03
$13.10M
derived: sum of 2 quarters · filed 2014-03-03
$19.38M
derived: sum of 3 quarters · filed 2014-03-03
$24.92M
10-K · filed 2014-03-03
2011-09-30$6.89M
10-Q · filed 2012-10-31
$13.16M
derived: sum of 2 quarters · filed 2012-10-31
$18.71M
10-Q · filed 2012-10-31
2011-06-30$6.28M
10-Q · filed 2012-08-01
$11.82M
10-Q · filed 2012-08-01
2011-03-31$5.54M
10-Q · filed 2012-05-02
2010-12-31$19.01M
10-K · filed 2013-02-26
2009-12-31$20.00M
10-K · filed 2012-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
OMEROS CORP (OMER)United States$1.456B5.50
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10